People s United Financial Inc. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 0.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,770 shares of the medical equipment provider’s stock after selling 287 shares during the period. People s United Financial Inc.’s holdings in Boston Scientific Corporation were worth $964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the business. Swiss National Bank increased its position in Boston Scientific Corporation by 2.9% during the 2nd quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock valued at $154,814,000 after purchasing an additional 156,800 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Boston Scientific Corporation by 10.5% in the 2nd quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock valued at $253,854,000 after purchasing an additional 867,983 shares in the last quarter. Koch Industries Inc. bought a new stake in shares of Boston Scientific Corporation in the 1st quarter valued at about $307,000. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Boston Scientific Corporation by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after purchasing an additional 3,033,800 shares in the last quarter. Finally, Bellevue Group AG raised its holdings in shares of Boston Scientific Corporation by 4.0% in the 1st quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock valued at $14,226,000 after purchasing an additional 22,000 shares in the last quarter. Institutional investors own 90.44% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at 29.02 on Wednesday. The stock’s 50 day moving average is $28.06 and its 200 day moving average is $26.92. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.50. The firm has a market capitalization of $39.82 billion, a P/E ratio of 51.91 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the prior year, the business earned $0.27 EPS. Boston Scientific Corporation’s quarterly revenue was up 6.2% compared to the same quarter last year. Equities analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

Several equities analysts recently issued reports on BSX shares. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $31.00 price objective (up previously from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada restated a “buy” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Boston Scientific Corporation in a report on Tuesday. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $31.00 target price (up previously from $29.50) on shares of Boston Scientific Corporation in a research report on Friday, June 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Boston Scientific Corporation presently has a consensus rating of “Buy” and an average target price of $30.12.

In other Boston Scientific Corporation news, SVP John Bradley Sorenson sold 2,100 shares of Boston Scientific Corporation stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $27.15, for a total value of $57,015.00. Following the transaction, the senior vice president now directly owns 18,880 shares in the company, valued at approximately $512,592. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific Corporation stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $29.24, for a total value of $323,423.64. Following the completion of the transaction, the executive vice president now owns 174,681 shares in the company, valued at $5,107,672.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 276,318 shares of company stock worth $7,567,967. 0.74% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “People s United Financial Inc. Lowers Position in Boston Scientific Corporation (BSX)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/04/people-s-united-financial-inc-lowers-position-in-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.